Abstract Number: 0727 • ACR Convergence 2024
Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study
Background/Purpose: Significant progress has been achieved over the course of recent time in elucidating the complex underlying pathophysiological mechanisms of ANCA associated vasculitis (AAV). Despite…Abstract Number: 0867 • ACR Convergence 2024
Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) care faces challenges due to a shortage of healthcare providers, an increasing patient population and the remote locations of many patients.…Abstract Number: 1113 • ACR Convergence 2024
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Background/Purpose: IgG4-RD presents various clinical manifestations, making it challenging to assess treatment responses. B-cell depletion agents such as Rituximab (RTX) are used in refractory cases.…Abstract Number: 1357 • ACR Convergence 2024
Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial
Background/Purpose: Glomerular filtration rate (GFR) is difficult to measure in patients with RA since creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate GFR due to…Abstract Number: 1638 • ACR Convergence 2024
Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis
Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally…Abstract Number: 1839 • ACR Convergence 2024
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…Abstract Number: 2232 • ACR Convergence 2024
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…Abstract Number: 0491 • ACR Convergence 2024
Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…Abstract Number: 0636 • ACR Convergence 2024
Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)
Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…Abstract Number: 0738 • ACR Convergence 2024
Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA
Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…Abstract Number: 0871 • ACR Convergence 2024
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…Abstract Number: 1121 • ACR Convergence 2024
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 96
- Next Page »